Maze Therapeutics (NASDAQ:MAZE) Insider Sells $205,050.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total transaction of $205,050.00. Following the completion of the transaction, the insider owned 26,250 shares in the company, valued at $717,675. This represents a 22.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $28.02, for a total transaction of $210,150.00.

Maze Therapeutics Stock Performance

Maze Therapeutics stock opened at $26.92 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. The company has a market capitalization of $1.49 billion, a PE ratio of -10.64 and a beta of 2.22. The company has a 50 day moving average price of $27.36 and a 200-day moving average price of $34.01. Maze Therapeutics, Inc. has a fifty-two week low of $12.81 and a fifty-two week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. As a group, equities analysts forecast that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MAZE has been the topic of several research reports. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Finally, Truist Financial dropped their target price on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 14th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Maze Therapeutics has an average rating of “Buy” and an average price target of $66.00.

Institutional Trading of Maze Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP bought a new position in shares of Maze Therapeutics in the 1st quarter worth $917,000. Bank of America Corp DE boosted its position in Maze Therapeutics by 961.3% during the first quarter. Bank of America Corp DE now owns 195,084 shares of the company’s stock valued at $5,823,000 after purchasing an additional 176,703 shares in the last quarter. Royal Bank of Canada boosted its position in Maze Therapeutics by 214.1% during the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock valued at $61,000 after purchasing an additional 1,383 shares in the last quarter. Exome Asset Management LLC purchased a new position in Maze Therapeutics in the first quarter valued at about $2,642,000. Finally, The Manufacturers Life Insurance Company grew its stake in Maze Therapeutics by 111.3% in the first quarter. The Manufacturers Life Insurance Company now owns 14,570 shares of the company’s stock valued at $435,000 after purchasing an additional 7,673 shares during the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.